Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary new platform.
All the latest company news, press releases and updates from Epitopea.

About Epitopea

Revealing the true targets for next generation immunotherapies.
Learn More

We Are Epitopea

We believe better cancer therapies are needed to transform people’s lives. We are developing accessible off-the-shelf cancer immunotherapies that will deliver durable benefits.
Learn more
We are a global leader in exploiting a novel class of untapped tumour-specific antigens (TSAs), CryptigenTM TSAs, designed to treat a broad patient population.
Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.

Our technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, which we have exclusively licensed from the Université de Montréal (UdeM), along with the rights to exploit large sets of CryptigenTM TSAs in solid and hematological cancers.

Meet our Team

Jon Moore
CEO
Steven Klein
CBO
Dr. Claude Perreault
Co-Founder
Dr. Pierre Thibault
Co-Founder

Investors

We recently successfully closed a £10 million seed round.

The company has backing from international life sciences investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, and the Fonds de solidarité FTQ.

Partners

In addition to its top-tier international investors, Epitopea is also proud to be supported by a strong network of partners from the public and private sectors, which provide us with R&D and related support. Furthermore, Harrington Discovery Institute and Novateur Ventures also made equity investments in Epitopea.
Revealing the true targets for next generation immunotherapies
© 2022 Epitopea Ltd | All Rights Reserved
Created by FDM Digital